definiens: means ( a ) for all Modified RNA Products, on a country - by - country basis, the period of time from the FirstCommercial Sale of the first Modified RNA Product in such country in the Field until the later of ( i ) the period during which the manufacture, sale, offer for sale or importation of such first Modified RNA Product in such country would infringe, but for the license granted herein, a ValidClaim Covering such first Modified RNA Product in such country, ( ii ) the tenth ( 10th ) anniversary of the date of the First Commercial Sale ofsuch first Modified RNA Product in such country in the Field, or ( iii ) lapse of regulatory data exclusivity for such first Modified RNA Productin such country ( or region to which the country is a member state ) ; and ( b ) for all Replicon Products, on a country - by - country basis, theperiod of time from the First Commercial Sale of the first Replicon Product in such country in the Field until the later of ( i ) the period duringwhich the manufacture, sale, offer for sale or importation of such first Replicon Product in such country would infringe, but for the licensegranted herein, a Valid Claim Covering such first Replicon Product in such country, ( ii ) the tenth ( 10th ) anniversary of the date of the FirstCommercial Sale of such first Replicon Product in such country in the Field, or ( iii ) lapse of regulatory data exclusivity for such first RepliconProduct in such country ( or region to which the country is a member state ) . If a Product comprises both Modified RNA Technology andReplicon Technology ( ), where it is the first Product to achieve a First Commercial Sale in any country in the Territory, itshall be 14classified by [COMPANY] as either a Modified RNA Product or a Replicon Product ( but not both ) for the purposes of this definition in such countryuntil such time as a different Product that comprises either Modified RNA Technology or Replicon Technology ( but not both ) achieves a FirstCommercial Sale in such country, whereupon the second Product shall be classified under this definition as either a Modified RNA Productor Replicon Product according to the technology it comprises and the Combined Product shall thereafter be deemed to fall within the otherdefinition . If a Combined Product is the second Product to achieve a First Commercial Sale in a country in the Territory, it will be deemed tofall within the definition of Modified RNA Product if the first Product was a Replicon Product and vice versa . For the avoidance of doubt, percountry there will be no more than two ( 2 ) different Royalty Terms for all Products in such country